Kallambettu Veena, York Justine Dallal, Vasilopolous Terrie, Hutcheson Katherine, Plowman Emily
Aerodigestive Research Core Laboratory, The Ohio State University, Columbus, Ohio, USA.
Department of Otolaryngology-Head & Neck Surgery, The Ohio State University, Columbus, Ohio, USA.
Neurogastroenterol Motil. 2025 Jun;37(6):e70008. doi: 10.1111/nmo.70008. Epub 2025 Mar 3.
Although dysphagia is prevalent in persons with amyotrophic lateral sclerosis (pALS) and is associated with morbidity and mortality, no validated outcomes currently exist for the gold standard videofluoroscopy (VF) exam. We therefore sought to psychometrically validate the Dynamic Imaging Grade of Swallowing Toxicity (DIGEST) scale in pALS.
One hundred pALS attended a research evaluation and underwent a standardized VF and validated clinical outcomes of oral intake (FOIS), perceived swallowing impairment (EAT-10), and ALS disease progression (ALSFRS-Revised). Duplicate, independent, and blinded VF ratings were completed using the DIGEST and MBSImP scales. Weighted kappa, ANOVAs (Tukey's HSD, Welch's correction), and Chi-square analyses were performed to determine intra- and inter-rater reliability, criterion validity, and construct validity of the DIGEST scale for use in pALS.
The mean age was 64.4(SD = 10.4), 50% were male, and the average ALS duration was 28.2 months (SD = 22.2). Excellent intra-rater (kappa = 0.92-1.0) and inter-rater (kappa = 0.94) reliability were noted for DIGEST ratings. DIGEST grades significantly discriminated pharyngeal pathophysiology (MBSImP, F(3,96) = 24.7, p < 0.0001), perceived dysphagia (EAT-10, F(3,40) = 20.8, p < 0.0001), oral intake (FOIS, X:25.4, df = 3, p < 0.0001), ALS bulbar disease progression (ALSFRS-bulbar, F(3,93) = 20.8, p < 0.0001) with main effects noted for all analyses. Post hoc pairwise comparisons noted differences across all DIGEST grades with the exception of DIGEST 2 versus 3 (moderate vs. severe dysphagia), p > 0.05.
These data confirm that the DIGEST scale is a reliable and valid VF outcome for use in pALS to distinguish normal versus impaired swallowing and mild versus moderate or severe dysphagia for use in clinical practice and as a clinical trial endpoint marker.
尽管吞咽困难在肌萎缩侧索硬化症患者(pALS)中很常见,且与发病率和死亡率相关,但目前尚无经过验证的金标准视频荧光吞咽造影检查(VF)结果。因此,我们试图从心理测量学角度验证pALS患者的吞咽毒性动态成像分级(DIGEST)量表。
100例pALS患者参加了一项研究评估,接受了标准化的VF检查,并验证了口服摄入量(FOIS)、感知吞咽障碍(EAT-10)和ALS疾病进展(修订版ALSFRS)的临床结果。使用DIGEST量表和MBSImP量表完成了重复、独立且盲法的VF评分。进行加权kappa检验、方差分析(Tukey's HSD、Welch校正)和卡方分析,以确定DIGEST量表在pALS患者中的评分者内和评分者间信度、效标效度和结构效度。
平均年龄为64.4岁(标准差=10.4),50%为男性,ALS平均病程为28.2个月(标准差=22.2)。DIGEST评分显示出优秀的评分者内信度(kappa=0.92-1.0)和评分者间信度(kappa=0.94)。DIGEST分级能显著区分咽部病理生理学(MBSImP,F(3,96)=24.7,p<0.0001)、感知吞咽困难(EAT-10,F(3,40)=20.8,p<0.0001)、口服摄入量(FOIS,X:25.4,自由度=3,p<0.0001)、ALS延髓疾病进展(ALSFRS-延髓,F(3,93)=20.8,p<0.0001),所有分析均显示出主效应。事后两两比较发现,除DIGEST 2级与3级(中度与重度吞咽困难)外,所有DIGEST分级之间均存在差异,p>0.05。
这些数据证实,DIGEST量表是一种可靠且有效的VF结果,可用于pALS患者,以区分正常吞咽与吞咽受损以及轻度与中度或重度吞咽困难,用于临床实践和作为临床试验终点标志物。